Barclays (LON:BARC) analyst Gaurav Jain maintained a Hold rating on Canopy Growth (NASDAQ:CGC) on Wednesday, setting a price target of C$14, which is approximately 4.95% below the present share price of $11.62.
Jain expects Canopy Growth to post earnings per share (EPS) of -$0.03 for the fourth quarter of 2021.
The current consensus among 11 TipRanks analysts is for a Hold rating of shares in Canopy Growth, with an average price target of $13.35.
The analysts price targets range from a high of $22.09 to a low of $9.47.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $131.37 million and a net profit of -$210.46 million. The company's market cap is $4.57 billion.
According to TipRanks.com, Barclays analyst Gaurav Jain is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 4.3% and a 47.50% success rate.
Canopy Growth Corp. engages in the production and sale of medical cannabis. The company offers products including oils and concentrates, soft gel capsules and hemp. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.